Optimized psilocybin production in tryptophan catabolism‐repressed fungi
Microbial Biotechnology · 2024
DOI: 10.1111/1751-7915.70039 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Biotechnology, 2024. Verfasst von Slavica Janevska und 12 weiteren Autor:innen. Beteiligte Einrichtung: (Epi-)Genetic Regulation of Fungal Virulence, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute, Jena, German…. Hauptthemen laut MEDLINE: Psilocybin, Tryptophan, Saccharomyces cerevisiae, Aspergillus nidulans. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Social Fund, Bundesministerium für Bildung und Forschung, Deutsche Forschungsgemeinschaft-SFB 1127.
Abstract (Originalsprache)
The high therapeutic potential of psilocybin, a prodrug of the psychotropic psilocin, holds great promise for the treatment of mental disorders such as therapy‐refractory depression, alcohol use disorder and anorexia nervosa. Psilocybin has been designated a ‘Breakthrough Therapy’ by the US Food and Drug Administration, and therefore a sustainable production process must be established to meet future market demands. Here, we present the development of an in vivo psilocybin production chassis based on repression of l ‐tryptophan catabolism. We demonstrate the proof of principle in Saccharomyces cerevisiae expressing the psilocybin biosynthetic genes. Deletion of the two aminotransferase genes ARO8 / 9 and the indoleamine 2,3‐dioxygenase gene BNA2 yielded a fivefold increase of psilocybin titre. We transferred this knowledge to the filamentous fungus Aspergillus nidulans and identified functional ARO8 / 9 orthologs involved in fungal l ‐tryptophan catabolism by genome mining and cross‐complementation. The double deletion mutant of A. nidulans resulted in a 10‐fold increased psilocybin production. Process optimization based on respiratory activity measurements led to a final psilocybin titre of 267 mg/L in batch cultures with a space–time‐yield of 3.7 mg/L/h. These results demonstrate the suitability of our engineered A. nidulans to serve as a production strain for psilocybin and other tryptamine‐derived pharmaceuticals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- (Epi-)Genetic Regulation of Fungal Virulence, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute, Jena, Germany.
- Bio Pilot Plant, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute, Jena, Germany.
- Faculty of Biological Sciences, Friedrich Schiller University, Jena, Germany.
- Biobricks of Microbial Natural Product Syntheses, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute, Jena, Germany.
- Paleobiotechnology, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute, Jena, Germany.
- Fungal Informatics, Friedrich Schiller University, Jena, Germany.
ORCID-Profile: Slavica Janevska, Sophie Weiser, Sandra Hoefgen, Johann E Kufs
Förderung
- European Social Fund
- Bundesministerium für Bildung und Forschung
- Deutsche Forschungsgemeinschaft-SFB 1127
- Germany's Excellence Strategy-EXC 2051
- European Social Fund Plus
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Janevska, S., Weiser, S., Huang, Y., Lin, J., Hoefgen, S., Jojić, K., Barber, A. E., Schäfer, T., Fricke, J., Hoffmeister, D., Regestein, L., Valiante, V., & Kufs, J. E. (2024). Optimized psilocybin production in tryptophan catabolism‐repressed fungi. Microbial Biotechnology. https://doi.org/10.1111/1751-7915.70039
Vancouver
Janevska S, Weiser S, Huang Y, Lin J, Hoefgen S, Jojić K, et al. Optimized psilocybin production in tryptophan catabolism‐repressed fungi. Microbial Biotechnology. 2024. doi:10.1111/1751-7915.70039
BibTeX
@article{Janevska2024,
author = {Janevska, Slavica and Weiser, Sophie and Huang, Ying and Lin, Jun and Hoefgen, Sandra and Jojić, Katarina and Barber, Amelia E and Schäfer, Tim and Fricke, Janis and Hoffmeister, Dirk and Regestein, Lars and Valiante, Vito and Kufs, Johann E},
title = {Optimized psilocybin production in tryptophan catabolism‐repressed fungi},
journal = {Microbial Biotechnology},
year = {2024},
doi = {10.1111/1751-7915.70039}
}
EUVIMED